These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10676687)

  • 1. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators.
    Swedberg K; Bergh CH; Dickstein K; McNay J; Steinberg M
    J Am Coll Cardiol; 2000 Feb; 35(2):398-404. PubMed ID: 10676687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure.
    Dickstein K; Manhenke C; Aarsland T; McNay J; Wiltse C; Wright T
    Int J Cardiol; 2000 Sep; 75(2-3):167-76; discussion 176-7. PubMed ID: 11077130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
    Swedberg K; Bristow MR; Cohn JN; Dargie H; Straub M; Wiltse C; Wright TJ;
    Circulation; 2002 Apr; 105(15):1797-803. PubMed ID: 11956122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Dickstein K; Manhenke C; Aarsland T; Køpp U; McNay J; Wiltse C
    Am J Cardiol; 1999 Jun; 83(12):1638-44. PubMed ID: 10392868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
    Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
    Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
    Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.
    Brynne L; McNay JL; Schaefer HG; Swedberg K; Wiltse CG; Karlsson MO
    Br J Clin Pharmacol; 2001 Jan; 51(1):35-43. PubMed ID: 11167663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II and sympathetic activity in patients with congestive heart failure.
    Goldsmith SR; Hasking GJ; Miller E
    J Am Coll Cardiol; 1993 Apr; 21(5):1107-13. PubMed ID: 8384645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model.
    Van Kerckhoven R; van Veen TA; Boomsma F; Saxena PR; Schoemaker RG
    Eur J Pharmacol; 2000 May; 397(1):113-20. PubMed ID: 10844105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure.
    Grassi G; Turri C; Seravalle G; Bertinieri G; Pierini A; Mancia G
    Hypertension; 2001 Aug; 38(2):286-91. PubMed ID: 11509491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex.
    Szabo B; Fritz T; Wedzony K
    Br J Pharmacol; 2001 Sep; 134(2):295-304. PubMed ID: 11564647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy.
    Grassi G; Seravalle G; Bertinieri G; Turri C; Stella ML; Scopelliti F; Mancia G
    Clin Sci (Lond); 2001 Aug; 101(2):141-6. PubMed ID: 11473487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of digitalis on norepinephrine kinetics in congestive heart failure.
    Goldsmith SR; Simon AB; Miller E
    J Am Coll Cardiol; 1992 Oct; 20(4):858-63. PubMed ID: 1527296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of the inhibition by moxonidine and agmatine on the cardioaccelerator sympathetic outflow in pithed rats.
    Cobos-Puc LE; Villalón CM; Ramírez-Rosas MB; Sánchez-López A; Lozano-Cuenca J; Gómez-Díaz B; MaassenVanDenBrink A; Centurión D
    Eur J Pharmacol; 2009 Aug; 616(1-3):175-82. PubMed ID: 19527708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress.
    Wenzel RR; Mitchell A; Siffert W; Bührmann S; Philipp T; Schäfers RF
    Br J Clin Pharmacol; 2004 May; 57(5):545-51. PubMed ID: 15089806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance.
    Cohen-Solal A; Jacobson AF; Piña IL
    ESC Heart Fail; 2017 Nov; 4(4):499-506. PubMed ID: 29154422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.